



(51) International Patent Classification:

A61K 31/506 (2006.01) A61K 45/06 (2006.01)
A61K 31/519 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/EP2023/058261

(22) International Filing Date:

30 March 2023 (30.03.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/325,861 31 March 2022 (31.03.2022) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151 85
Södertälje (SE).

(72) Inventors: **FLOCH, Nicolas**; ASTRAZENECA UK LIMITED, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB). **MARTIN, Matthew Joseph**; ASTRAZENECA UK LIMITED, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB). **SMITH, Paul David**; ASTRAZENECA UK LIMITED, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB). **GRAZINI, Ursula**; ASTRAZENECA UK LIMITED, 1 Francis Crick

Avenue, Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB).


(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; Association 813, Eastbrook House, Shaftesbury Road, CAMBRIDGE Cambridgeshire CB2 8BF (GB).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS IN COMBINATION WITH AN AKT INHIBITOR FOR THE TREATMENT OF CANCER

Figure 1



(57) Abstract: The specification relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for use in the treatment of cancer, wherein the EGFR TKI is administered in combination with an AKT inhibitor.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*